| 1 (103) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA |  |
| 2 (166) | GlaxoSmithKline, United Kingdom | GBR | |
| 3 (185) | Sanofi, France | FRA | |
| 4 (187) | Sanofi, United States | USA | |
| 5 (190) | GlaxoSmithKline, United States | USA | |
| 6 (209) | Bristol-Myers Squibb Company, United States | USA | |
| 7 (213) | Hoffmann-La Roche Ltd, United States | USA | |
| 8 (226) | Genentech Inc | USA | |
| 9 (228) | AstraZeneca, Sweden | SWE | |
| 10 (239) | AstraZeneca, United Kingdom | GBR | |
| 11 (242) | Regeneron Pharmaceuticals Inc | USA | |
| 12 (243) | Novartis Institutes for Biomedical Research, United States | USA | |
| 13 (244) | Merck & Co Inc, United States | USA | |
| 14 (294) | AstraZeneca, United States | USA | |
| 15 (316) | Boehringer Ingelheim GmbH Germany | DEU | |
| 16 (336) | Novartis, Switzerland | CHE | |
| 17 (377) | Eli Lilly and Company, United States | USA | |
| 18 (385) | Janssen Biotech Inc | USA | |
| 19 (551) | Ormat Technologies, United States | USA | |
| 20 (582) | Boehringer Ingelheim, USA | USA | |
| 21 (617) | Bosch, Germany | DEU | |
| 22 (683) | Novartis Pharmaceuticals, United States | USA | |
|
